fda halts glp-1 What Changed? The FDA's Clarification on Compounded Drugs FDA creates 'green list' of

Patients receiving GLP-1 therapy demonstrated lower rates of advanced adenomas on surveillance colonoscopy, a finding particularly relevant given that adenoma prevention formed the evidentiary backbone for aspirins adoption in earlier prevention strategies

Patients with asthma, certain enzyme deficiencies, or chronic medical conditions should undergo proper evaluation before starting therapy

iu ny gp phn lm chm qu trnh lo ha da, gip da khe mnh v ti tr hn

doi: 10.1016/j.bbadis.2013.01.008 50 DumanR

GLP-1R is expressed in multiple cardiovascular cell types such as monocyte/macrophages, smooth muscle cells, endothelial cells, and cardiomyocytes